ArticleF1000Research2022
Gaidai reliability method for long-term coronavirus modelling.
Article in F1000Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- HIV deathrate prediction by Gaidai multivariate risks assessment method.Immunity, inflammation and disease · 2024Article
- Future worldwide coronavirus disease 2019 epidemic predictions by Gaidai multivariate risk evaluation method.Analytical science advances · 2024Article
- Article
- Floating wind turbines structural details fatigue life assessment.Scientific reports · 2023Article
- Dementia death rates prediction.BMC psychiatry · 2023Article
- Carbon Storage Tanker Lifetime Assessment.Global challenges (Hoboken, NJ) · 2023Article
- Oil tanker under ice loadings.Scientific reports · 2023Article
- Prediction of death rates for cardiovascular diseases and cancers.Cancer innovation · 2023Article
- Article
- Article
- Future world cancer death rate prediction.Scientific reports · 2023Article
- Multi-regional COVID-19 epidemic forecast in Sweden.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Novel coronavirus disease has been recently a concern for worldwide public health. To determine epidemic rate probability at any time in any region of interest, one needs efficient bio-system reliability approach, particularly suitable for multi-regional environmental and health systems, observed over a sufficient period of time, resulting in a reliable long-term forecast of novel coronavirus infection rate. Traditional statistical methods dealing with temporal observations of multi-regional processes do not have the multi-dimensionality advantage, that suggested methodology offers, namely dealing efficiently with multiple regions at the same time and accounting for cross-correlations between different regional observations. Methods: Modern multi-dimensional novel statistical method was directly applied to raw clinical data, able to deal with territorial mapping. Novel reliability method based on statistical extreme value theory has been suggested to deal with challenging epidemic forecast. Authors used MATLAB optimization software. Results: This paper described a novel bio-system reliability approach, particularly suitable for multi-country environmental and health systems, observed over a sufficient period of time, resulting in a reliable long-term forecast of extreme novel coronavirus death rate probability. Namely, accurate maximum recorded patient numbers are predicted for the years to come for the analyzed provinces. Conclusions: The suggested method performed well by supplying not only an estimate but 95% confidence interval as well. Note that suggested methodology is not limited to any specific epidemics or any specific terrain, namely its truly general. The only assumption and limitation is bio-system stationarity, alternatively trend analysis should be performed first. The suggested methodology can be used in various public health applications, based on their clinical survey data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.